Why join a multicentre breast cancer trial?
作者信息
Grieve R J
出版信息
Br Med J. 1979 Mar 24;1(6166):817. doi: 10.1136/bmj.1.6166.817.
Abstract
摘要
相似文献
1
Why join a multicentre breast cancer trial?为什么要参加多中心乳腺癌试验？
Br Med J. 1979 Mar 24;1(6166):817. doi: 10.1136/bmj.1.6166.817.
2
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.早期乳腺癌患者的辅助唑来膦酸治疗：AZURE（BIG 01/04）随机、开放标签、3 期临床试验的最终疗效分析。
Lancet Oncol. 2014 Aug;15(9):997-1006. doi: 10.1016/S1470-2045(14)70302-X. Epub 2014 Jul 15.
3
Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial.标准化槲寄生提取物PS76A2在化疗及随访期间可改善乳腺癌患者的生活质量：一项随机、安慰剂对照、双盲、多中心临床试验
Anticancer Res. 2006 Mar-Apr;26(2B):1519-29.
4
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).高危淋巴结阴性（N-）乳腺癌患者辅助化疗的最佳疗程：前瞻性随机多中心III期UNICANCER-PACS 05试验（UCBG-0106）的6年结果
Eur J Cancer. 2017 Jul;79:166-175. doi: 10.1016/j.ejca.2017.03.004. Epub 2017 May 11.
5
Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.辅助地舒单抗治疗乳腺癌（ABCSG-18）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2015 Aug 1;386(9992):433-43. doi: 10.1016/S0140-6736(15)60995-3. Epub 2015 May 31.
6
Two-stage implant-based breast reconstruction compared with immediate one-stage implant-based breast reconstruction augmented with an acellular dermal matrix: an open-label, phase 4, multicentre, randomised, controlled trial.基于假体的两阶段乳房重建与即刻一期基于假体的乳房重建联合脱细胞真皮基质的比较：一项开放标签、四期、多中心、随机、对照临床试验。
Lancet Oncol. 2017 Feb;18(2):251-258. doi: 10.1016/S1470-2045(16)30668-4. Epub 2016 Dec 22.
7
8
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.前瞻性多中心 Chemo-N0 试验的 10 年分析验证了美国临床肿瘤学会（ASCO）推荐的生物标志物 uPA 和 PAI-1 可用于指导淋巴结阴性乳腺癌患者的治疗决策。
Eur J Cancer. 2013 May;49(8):1825-35. doi: 10.1016/j.ejca.2013.01.007. Epub 2013 Mar 13.
9
National Cancer Patient Registry--Breast Cancer (NCPR-Breast Cancer).国家癌症患者登记处——乳腺癌（NCPR-乳腺癌）
Med J Malaysia. 2008 Sep;63 Suppl C:72-3.
10
Multimodal therapy for histological stage-II breast cancer. Multicentre Breast Cancer Chemotherapy Group.组织学II期乳腺癌的多模式治疗。多中心乳腺癌化疗组。
Lancet. 1977 Aug 20;2(8034):396-7.
本文引用的文献
1
Multimodal therapy from stage-II breast cancer.II期乳腺癌的多模式治疗
Lancet. 1978 Nov 18;2(8099):1092. doi: 10.1016/s0140-6736(78)91821-4.
Zotero 插件